Zymeworks BC Inc [NASDAQ: ZYME] surged by $5.38 during the normal trading session on Monday and reaching a high of $26.19 during the day while it closed the day at $23.9.
Zymeworks BC Inc stock has also gained 32.41% of its value over the past 7 days. However, ZYME stock has inclined by 69.50% in the 3 months of the year. Over the past six months meanwhile, it has gained 102.20% and gained 38.87% year-on date.
The market cap for ZYME stock reached $1.80 billion, with 75.14 million shares outstanding and 72.81 million shares in the current float. Compared to the average trading volume of 731.49K shares, ZYME reached a trading volume of 11144018 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Zymeworks BC Inc [ZYME]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ZYME shares is $30.18 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ZYME stock is a recommendation set at 1.17. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Zymeworks BC Inc shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on October 24, 2025. The new note on the price target was released on October 14, 2025, representing the official price target for Zymeworks BC Inc stock. Previously, the target price had yet another raise to $30, while B. Riley Securities analysts kept a Buy rating on ZYME stock.
The Price to Book ratio for the last quarter was 5.65, with the Price to Cash per share for the same quarter was set at 3.34.
ZYME stock trade performance evaluation
Zymeworks BC Inc [ZYME] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 32.41. With this latest performance, ZYME shares gained by 29.89% in over the last four-week period, additionally plugging by 102.20% over the last 6 months – not to mention a rise of 63.25% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZYME stock in for the last two-week period is set at 74.01, with the RSI for the last a single of trading hit 1.75, and the three-weeks RSI is set at 1.22 for Zymeworks BC Inc [ZYME]. The present Moving Average for the last 50 days of trading for this stock 17.57, while it was recorded at 19.99 for the last single week of trading, and 14.03 for the last 200 days.
Zymeworks BC Inc [ZYME]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Zymeworks BC Inc [ZYME] shares currently have an operating margin of -52.51% and a Gross Margin at 90.49%. Zymeworks BC Inc’s Net Margin is presently recorded at -47.16%.
Zymeworks BC Inc (ZYME) Capital Structure & Debt Analysis
According to recent financial data for Zymeworks BC Inc. ( ZYME), the Return on Equity (ROE) stands at -18.46%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -14.34%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Zymeworks BC Inc’s Return on Invested Capital (ROIC) is -18.90%, showcasing its effectiveness in deploying capital for earnings.
Zymeworks BC Inc (ZYME) Efficiency & Liquidity Metrics
Based on Zymeworks BC Inc’s (ZYME) latest financial statements, the Debt-to-Equity Ratio is 0.06%, indicating its reliance on debt financing relative to shareholder equity.
Zymeworks BC Inc (ZYME) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Zymeworks BC Inc. (ZYME) effectively leverages its workforce, generating an average of -$221783.22 per employee. The company’s liquidity position is robust, with a Current Ratio of 6.94% and a Quick Ratio of 6.94%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Zymeworks BC Inc [ZYME] stock
With the latest financial reports released by the company, Zymeworks BC Inc posted -0.31/share EPS, while the average EPS was predicted by analysts to be reported at -0.09/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.22. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ZYME. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Zymeworks BC Inc go to 21.33%.
Zymeworks BC Inc [ZYME]: Institutional Ownership
There are presently around $99.88%, or 100.69%% of ZYME stock, in the hands of institutional investors. The top three institutional holders of ZYME stocks are: ECOR1 CAPITAL, LLC with ownership of 13.44 million shares, which is approximately 17.59%. BVF INC/IL, holding 5.87 million shares of the stock with an approximate value of $$49.95 million in ZYME stocks shares; and BVF INC/IL, currently with $$44.35 million in ZYME stock with ownership which is approximately 6.8214%.
